N
NMD Pharma
Small-molecule therapies targeting neuromuscular diseases
About NMD Pharma
NMD Pharma is a biotech startup that specializes in the discovery and development of new treatments for neuromuscular diseases. These are conditions that affect the nerves that control your voluntary muscles, leading to muscle weakness and fatigue. The company's primary focus is on diseases such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth’s disease, and sarcopenia.
NMD Pharma's unique approach involves the development of small molecule inhibitors that target specific ion channels in skeletal muscles. Ion channels are like gates in the cell membrane that allow ions to pass through, and they play a crucial role in muscle contraction. By targeting these channels, NMD Pharma's treatments could potentially improve muscle function in patients with neuromuscular diseases.
The company operates in the pharmaceutical market, serving patients suffering from these debilitating conditions. Their business model revolves around the research, development, and eventual commercialization of their novel therapeutics. They generate revenue through the successful development and sale of these drugs.
NMD Pharma has shown significant promise, raising $47M in one of the largest Series A funding rounds in Europe. This funding is being used to advance their drugs to human clinical trials. The company has also been recognized for its work, winning the EY Entrepreneur Of The Year 2022 in the Life Sciences category and the INCUBA award for 'Startup of the Year 2022'.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Aarhus, Denmark
- Employees
- 83
- Open positions
- None listed
- Dealroom signal
- 89.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Disease, Biotech and Pharma, Nordic Rising Star 2022, Top 50 Nordic Rising Star 2022 Denmark, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2023 | $83M | $330M | Inkef · Jeito Capital · Novo Holdings · Roche Venture Fund | ↗ |
| EARLY VCOther financing | Feb 2022 | $39M | $209M | Inkef · Lundbeckfonden · Jeito Capital · Novo Holdings | ↗ |
Growth signals
Latest recorded traffic for NMD Pharma is 14K monthly website visits, up 16.7% over the last three months. NMD Pharma's team grew 10.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Novo Seeds
Series A7 investors entered at this stage
Inkef
Roche Venture Fund
Lundbeckfonden Ventures
Novo Ventures
Jeito Capital
Lundbeckfonden
Novo Holdings
Other known investors1 additional known investor
Aarhus University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NMD Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NMD Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.